Saturday, September 19, 2015 11:33:41 AM
I tell you what brother longs...there are still plenty of people out there who would run to buy AEZS if they would just know about us... Now we saw some very big investor entering and that fund/institution knows exactly that AEZS is a long-term investment. They see the true value here. That value what us longs have seen for long time now...
SHORTING
Naked shorting attempts have most likely started investigations and funds may now think twice before doing it again. There were approximately 48M stocks shorted or...shorted naked before last Fri;O). I believe we are done shorting now. At least those who were not part of naked ring learned their lesson in a hard way.
UPTREND WILL MOST LIKELY CONTINUE
Price will most likely continue to rise towards $0.20+ area when news get closer. If news is good we will most likely get closer (if not above) $1. Tax selling is most likely over now too and on last Fri some late fools learned their lesson painfully. Like I said before all of the all-time-lows were artificially created. Someone wanted to heavily accumulate AEZS shares and it was done from the 'dilution' shadow. Most of the investors did not even see those huge bids because they concentrated on less important things like what is the O/S, how much did the price change without seeing the patterns and doing analysis crooks wanted them to do. They were fooled to play with someone elses rules. Crooks saw their moment and used that...loaded AEZS all the way down. You still have your shares or did you give those for crooks 'for free'?
BUYOUT MAY STILL BE COMING
We may have also seen open market buyout attempt. Who...it is impossible to say...but like I said before big pharma CEOs know that buying AEZS under 0.50 is much cheaper than launching new drug development study from zero to phase 3...
GOING ABOVE $1 IS VERY LIKELY
AEZS should be able to go above $1.50 without any R/S. Like I said before this company should be trading around $0.50-$0.70 like most of the companies with phase 2 drugs...only thing is AEZS has phase 3 drugs so it should be trading around $1.20-$1.40 even now. If we get immediate FDA approval I believe we touch $2+ pretty fast and $40 in 2 years.
WHAT IS THE PURPOSE OF FDA?
The purpose of FDA is to ensure people get safe and effective medicines they urgently need... In AEZS's case patients will most likely die without this medicine. Patients need alternative treatment to surgery. I see we have heavy chance to become first FDA approved drug for Endometrial Cancer.
"FDA is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.
FDA is also responsible for advancing the public health by helping to speed innovations that make medicines more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medicines and foods to maintain and improve their health. FDA also has responsibility for regulating the manufacturing, marketing and distribution of tobacco products to protect the public health and to reduce tobacco use by minors.
Finally, FDA plays a significant role in the Nation’s counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats."
http://www.fda.gov/AboutFDA/WhatWeDo/
IS AEZS A STRONG BUY OR NOT?
I strongly believe AEZS is still one of the best buys in NASDAQ...and big investors know that. AEZS has Phase 3 trial in endometrial concer (Zoptarelin doxorubicin...news out early October 2015...may be the first FDA approved...), Confirmatory Phase 3 trial with Marcrilen in AGHD and started to sell e.g. EMD Serono's Saizen. There may be other interesting new Pipe updates this year.
STRONG BUY
Recent AEZS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/13/2024 01:20:29 PM
- Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 06/13/2024 01:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/10/2024 05:31:28 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 06/06/2024 05:46:51 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/05/2024 04:15:07 AM
- Aeterna Zentaris and Ceapro Complete Merger Transaction • GlobeNewswire Inc. • 06/03/2024 01:15:41 PM
- Aeterna Zentaris and Ceapro Complete Merger Transaction • GlobeNewswire Inc. • 06/03/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/31/2024 01:58:07 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/31/2024 01:56:49 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/31/2024 01:56:35 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/31/2024 01:55:30 AM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 05/30/2024 01:31:16 AM
- Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date • GlobeNewswire Inc. • 05/29/2024 10:35:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 12:00:34 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 05/17/2024 12:00:32 PM
- Aeterna Zentaris Announces Details Regarding Transaction with Ceapro • GlobeNewswire Inc. • 05/17/2024 12:00:00 PM
- Aeterna Zentaris Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 10:00:00 PM
- Aeterna Zentaris Announces Effective Date of Share Consolidation • GlobeNewswire Inc. • 05/01/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 03/27/2024 12:05:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM